SPONSORED
By Elric Langton | 2 March 2023
I have a financial interest in Poolbeg Pharma.
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a leading infectious disease-focused biopharmaceutical company, announces the data readout from the bacterial lipopolysaccharide ('LPS') human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulatoโฆ